UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000052449
Receipt number R000059846
Scientific Title Safety evaluation of long-term (12 weeks) intake of food containing Lactobacillus brevis subsp. coagulans (Labre) .
Date of disclosure of the study information 2023/10/10
Last modified on 2023/10/06 18:00:42

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Safety evaluation of long-term (12 weeks) intake of food containing Lactobacillus brevis subsp. coagulans (Labre) .

Acronym

Safety evaluation of long-term (12 weeks) intake of food containing Lactobacillus brevis subsp. coagulans (Labre) .

Scientific Title

Safety evaluation of long-term (12 weeks) intake of food containing Lactobacillus brevis subsp. coagulans (Labre) .

Scientific Title:Acronym

Safety evaluation of long-term (12 weeks) intake of food containing Lactobacillus brevis subsp. coagulans (Labre) .

Region

Japan


Condition

Condition

Healthy adult women

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm safety of continuous intake (12weeks) of foods containing Labre.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Change of the values of physical test, hematological test, blood biochemistry test and urinalysis, and the number of adverse events.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Test food: Food containing Labre

Interventions/Control_2

Placebo food: Food free of Labre

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

65 years-old >

Gender

Female

Key inclusion criteria

(1) Subjects who participated and completed the Study to confirm the effect of continuous ingestion of food containing Lactobacillus brevis susp. coagulans (Labre) on skin moisture (UMIN000051886).
(2) Subjects who have received sufficient explanations about the purpose and content of this study, have the ability to consent, volunteer to participate in this study in writing with a good understanding.

Key exclusion criteria

(1) Subjects who are participating in clinical research or monitoring (food, pharmaceuticals, cosmetics) other than this research, or plan to participate during this research period
(2) Subjects who are judged to be inappropriate for this study with other reasons by the principal investigator.

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Kazuhiko
Middle name
Last name Takano

Organization

Medical Corporation Hokubukai Utsukushigaoka Hospital

Division name

Clinical Pharmacology Center

Zip code

004-0839

Address

61-1, Sinei, Kiyota-ku, Sapporo, Hokkaido 004-0839 Japan

TEL

011-882-0111

Email

takano@ughp-cpc.jp


Public contact

Name of contact person

1st name Takuya
Middle name
Last name Matsuda

Organization

Medical Corporation Hokubukai Utsukushigaoka Hospital

Division name

Clinical Pharmacology Center

Zip code

004-0839

Address

61-1, Sinei, Kiyota-ku, Sapporo, Hokkaido 004-0839 Japan

TEL

011-882-0111

Homepage URL


Email

matsuda@ughp-cpc.jp


Sponsor or person

Institute

Medical Corporation Hokubukai Utsukushigaoka Hospital

Institute

Department

Personal name



Funding Source

Organization

Shinwayakuhin Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Corporation Hokubukai Utsukushigaoka Hospital Ethics Review Committee

Address

61-1, Shinei, Kiyota-ku, Sapporo, Hokkaido 004-0839 Japan

Tel

011-882-0111

Email

matsuda@ughp-cpc.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 10 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

40

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2023 Year 09 Month 22 Day

Date of IRB

2023 Year 10 Month 05 Day

Anticipated trial start date

2023 Year 10 Month 10 Day

Last follow-up date

2023 Year 11 Month 13 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2023 Year 10 Month 10 Day

Last modified on

2023 Year 10 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000059846


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name